1a/1b Subtype Profiling of Nonnucleoside Polymerase Inhibitors of Hepatitis C Virus
- 15 March 2010
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 84 (6) , 2923-2934
Abstract
The RNA-dependent RNA polymerase (NS5B) of hepatitis C virus (HCV) is an unusually attractive target for drug discovery since it contains five distinct drugable sites. The success of novel antiviral therapies will require nonnucleoside inhibitors to be active in at least patients infected with HCV of subtypes 1a and 1b. Therefore, the genotypic assessment of these agents against clinical isolates derived from genotype 1-infected patients is an important prerequisite for the selection of suitable candidates for clinical development. Here we report the 1a/1b subtype profiling of polymerase inhibitors that bind at each of the four known nonnucleoside binding sites. We show that inhibition of all of the clinical isolates tested is maintained, except for inhibitors that bind at the palm-1 binding site. Subtype coverage varies across chemotypes within this class of inhibitors, and inhibition of genotype 1a improves when hydrophobic contact with the polymerase is increased. We investigated if the polymorphism of the palm-1 binding site is the sole cause of the reduced susceptibility of subtype 1a to inhibition by 1,5-benzodiazepines by using reverse genetics, X-ray crystallography, and surface plasmon resonance studies. We showed Y415F to be a key determinant in conferring resistance on subtype 1a, with this effect being mediated through an inhibitor- and enzyme-bound water molecule. Binding studies revealed that the mechanism of subtype 1a resistance is faster dissociation of the inhibitor from the enzyme.Keywords
This publication has 50 references indexed in Scilit:
- Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseAntimicrobial Agents and Chemotherapy, 2009
- Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C VirusJournal of Biological Chemistry, 2009
- Settling the “score” with liver cancerJournal of Hepatology, 2009
- 1,5-Benzodiazepines, a Novel Class of Hepatitis C Virus Polymerase Nonnucleoside InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Development of Intergenotypic Chimeric Replicons To Determine the Broad-Spectrum Antiviral Activities of Hepatitis C Virus Polymerase InhibitorsAntimicrobial Agents and Chemotherapy, 2008
- Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796Antimicrobial Agents and Chemotherapy, 2008
- Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee ModelAntimicrobial Agents and Chemotherapy, 2007
- Binding-Site Identification and Genotypic Profiling of Hepatitis C Virus Polymerase InhibitorsJournal of Virology, 2007
- Treating viral hepatitis C: efficacy, side effects, and complicationsGut, 2006
- Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimerasProceedings of the National Academy of Sciences, 2006